IntroductIon It has been shown that formation of denser and poorly lysable fibrin clots is observed in elderly patients with peripheral artery disease (PAD).
IntroductIon Peripheral artery disease (PAD) has a prevalence between 3% and 10% in the general population and is associated with a 6-fold increase in cardiovascular mortality.
1 PAD is strongly associated with advanced age. Patients with early onset of the disease represent only 1% of the PAD population but have a particularly progressive disease with early involvement of carotid and coronary arteries.
2 Higher risk of failed bypass surgery leading to amputations is reported in patients with premature PAD compared with their older counterparts. 3 Despite the fact that traditional atherosclerosis risk factors explain 75% to 95% of PAD cases, they are less common among younger patients. 4, 5 Enhanced inflammation has been implicated in premature PAD. In a cross-sectional community-based study, the odds ratios of PAD in the highest C-reactive protein (CRP) quartile vs. the 3 lower quartiles were larger for patients aged less than 55 years compared with older subjects.
6 Coexisting coronary artery disease (CAD) and elevated plasma fibrinogen were associated with premature peripheral vascular disease. 7 It has if a significant (≥50%) occlusion of the common or internal carotid artery was found based on the NASCET protocol (North American Symptomatic Carotid Endarterectomy Trial). 24 Multisite atherosclerosis was diagnosed if PAD was accompanied by CAD and/or carotid artery stenosis. Diabetes and stroke were diagnosed according to the World Health Organization criteria.
The local Chamber of Physicians' Ethical Committee approved the study, and patients provided written informed consent in accordance with the Declaration of Helsinki.
laboratory investigations Blood was drawn from an antecubital vein with minimal stasis after an overnight fast between 8 to 10 a.m. Glucose, lipid profile, and creatinine were assayed by routine laboratory techniques. Fibrinogen was determined using the Clauss method and high-sensitivity CRP by immunoturbidimetry (Roche, Manheim, Germany). The commercially available immunoenzymatic assays were used to determine D-dimer, tissue-type plasminogen activator antigen (tPA:Ag) and PAI-1 antigen (PAI-1:Ag) (all, American Diagnostica, Greenwich, Connecticut, United States). All intraassay and interassay coefficients of variation were below 7%.
Plasma fibrin clot analysis Plasma fibrin clot variables were determined at least in duplicate by technicians blinded to the origin of the samples (intraassay and interassay coefficients of variation, 5% to 8%, for all variables), as described.
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1 Fibrin clot permeation using a pressure--driven system, with calculation of a permeation coefficient (K s ), which indicates the pore size. Lower K s values indicate reduced permeability. 2 The lag phase of the turbidity curve, which reflects the time required for initial protofibril formation and maximum absorbance at 405 nm at the plateau phase (∆Abs), indicating the number of protofibrils per fiber. 3 Fibrinolysis in the presence of recombinant tPA (rtPA, Boerhinger Ingelheim, Ingelheim, Germany) added simultaneously with human thrombin was evaluated. Clot lysis time was defined as the time required for a 50% decrease in clot turbidity at 405 nm (t 50% ), induced by 1 µg/ml rtPA. 4 Fibrin clots formed as described above were perfused with the same buffer containing 0.2 µmol/l rtPA. The lysis rate was determined by measuring the levels of D-dimer, a marker of plasmin--mediated fibrin degradation, every 20 minutes in the effluent. The maximum rates of an increase in D-dimer levels (D-D rate ), and their maximum values (D-D max ) detected at 80 or 100 minutes were analyzed. statistical analysis Continuous variables were expressed as mean ± standard deviation for normally distributed variables and as median and interquartile range for nonnormally distributed variables. Continuous variables were checked been shown that fibrinogen, CRP, serum amyloid A, and D-dimer are higher in PAD patients, and CRP is associated with severity of the disease. 8 Higher plasma levels of D-dimer, plasminogen, prothrombin fragment 1 + 2, and plasminogen activator inhibitor type 1 (PAI-1) were observed in a small sample of patients with PAD compared with healthy controls. 9 CRP, fibrinogen, and D-dimer have also been associated with progression of PAD symptoms. 10 Thrombophilia is observed in 15% to 30% of patients with PAD presenting at a young age. 11, 12 High thrombin activatable fibrinolysis inhibitor (TAFI) levels have been reported in this patient group. 13 The role of these factors in the pathogenesis of PAD remains to be elucidated.
The Recently, unfavorably altered fibrin clot properties have been demonstrated in middle-aged and elderly PAD patients.
21 Lower clot permeability and prolonged clot lysis were associated with progression of the disease during follow-up. 21 First-degree relatives of PAD patients had similarly altered clot characteristics as the patients. 22 We hypothesized that premature PAD is associated with particularly unfavorable fibrin clot characteristics compared with elderly patients with PAD.
PAtIents And methods
We recruited 31 consecutive patients with premature PAD, defined as age at symptom onset of 55 years or less and 32 patients with PAD aged 56 years or more. PAD was defined as intermittent claudication and the ankle brachial index (ABI) of 0.9 or less measured using the established methods.
23 The exclusion criteria were a history of VTE, recent (<6 months) arterial thrombotic event, cancer, liver cirrhosis, renal failure (serum creatinine >177 µmol/l), any acute illness, pregnancy, and anticoagulant therapy. None of the patients took clopidogrel at the time of enrollment. Forty age-and sex-matched volunteers from among outpatients and hospital staff with the ABI values above 0.9 served as controls. CAD was defined as a history of MI, coronary revascularization, or coronary stenosis (>50% of the lumen diameter) on coronary angiography. Carotid artery stenosis was diagnosed independent factors influencing fibrin clot parameters, we used a multiple regression analysis in which a P value of 0.05 or less in a simple regression analysis was used as a criterion for entry into the model. A multiple regression analysis was performed with the manual selection of predictors as well as with backward and forward stepwise regression. A P value less than 0.05 was considered statistically significant. All statistical analyses were performed with STATISTICA for Windows 10.0.
results Premature peripheral artery disease vs.
controls The 2 groups did not differ with regard to demographics (tAble 1) . Hypertension, for normal distribution by the Shapiro-Wilk statistic and compared by the analysis of variance when normally distributed or by the Kruskal-Wallis test for nonnormally distributed variables. The post-hoc Sheffé test was used to evaluate precise intergroup statistics. Categorical variables were compared by the χ 2 test or Fisher's exact test as appropriate. The Pearson or Spearman rank correlation coefficients were calculated to test the association between 2 variables with a normal or nonnormal distribution, respectively. A covariance analysis adjusted for potential confounders, including cardiovascular risk factors and medications, was used to evaluate intergroup differences in fibrin clot parameters. To identify Values are given as mean ± SD, median (IQR), or number (percentage).
P 1 refers to comparisons between premature PAD and controls; P 2 refers to comparisons between premature and older PAD.
Abbreviations: ABI -ankle brachial index, ACEIs -angiotensin-converting enzyme inhibitors, BMI -body mass index; CRP -C-reactive protein, HDL-Chigh-density lipoprotein cholesterol, IQR -interquartile range, LDL-C -low-density lipoprotein cholesterol, MI -myocardial infarction, NA -not available, NS -nonsignificant, PAD -peripheral artery disease, PAI-1:Ag -plasminogen activator inhibitor-1 antigen, SD -standard deviation, TC -total cholesterol, TG -triglycerides, tPA:Ag -tissue-type plasminogen activator antigen between CRP and K s (r = -0.43, P = 0.02), and no correlations between CRP and the remaining fibrin variables. No associations were observed between clot variables and the body mass index. Interestingly, there were no correlations between the ABI or pack-years and fibrin clot parameters in premature PAD. We observed no differences between patients with multisite atherosclerosis and the remainder, between diabetic and nondiabetic patients, or current vs. former smokers (data not shown). As expected, plasma fibrinogen correlated with ∆Abs (r = 0.71, P <0.001), lag phase (r = -0.41, P = 0.03), K s (r = -0.53, P = 0.002), t 50% (r = 0.45, P = 0.01), and D-D rate (r = -0.63, P <0.001) in premature PAD. Age correlated with t 50% (r = 0.51, P = 0.004).
In older patients with PAD, ABI was strongly positively correlated with K s (r = 0.91, P <0.001) and D-D rate (r = 0.64, P <0.001) and negatively with t 50% (r = -0.66, P <0.001), ∆Abs (r = -0.47, P = 0.006), and D-D max (r = -0.72, P <0.001). There was a positive correlation between ∆Abs and pack-years in that group (r = -0.52, P = 0.002). There were no correlations between CRP and fibrin clot parameters in older PAD patients. We observed no differences between patients with multisite atherosclerosis and the remainder, as well as between diabetic and nondiabetic patients in this group (data not shown). In older patients with PAD, current smokers had lower ∆Abs compared with former smokers (0.77 ±0.27 vs. 0.92 ±0.06, P = 0.045). In older PAD patients, fibrinogen correlated with ∆Abs (r = 0.55, P <0.001), K s (r = -0.72, P <0.001), t 50% (r = 0.70, P <0.001), D-D max (r = 0.78, P <0.001), and D-D rate (r = -0.59, P <0.001).
In all patients with PAD, there were inverse correlations between ABI and t 50% (r = -0.42, P <0.001), D-D max (r = -0.30, P = 0.02), PAI-1 (r = -0.40, P = 0.001), plasma D-dimer (r = -0.32 P = 0.01), and fibrinogen (r = -0.28; P = 0.002), while the ABI was positively correlated with K s (r = 0.52, P <0.001). There was a positive correlation between CRP and ∆Abs (r = 0.53, P <0.001) and t 50% (r = 0.28, P = 0.03) and a negative correlation diabetes, current smoking, and history of MI as well as carotid or coronary stenosis were more frequent in premature PAD patients. Atherosclerotic plaques in the arteries of the lower limbs were found in the iliac or femoral arteries in 25 premature PAD patients (80.6%) and in the distal segments (popliteal artery and below) in 2 premature PAD patients (6.5%). In 4 patients (12.9%), significant occlusions were found both in the proximal and distal segments of the lower limb arteries.
Glucose and CRP were higher in premature PAD group. Plasma PAI-1 was 8-fold higher (P <0.001) and tPA 90% higher in premature PAD (P <0.0001). Plasma D-dimer was similar in both groups (tAble 1) . Compared with controls, premature PAD patients had 32% lower clot permeability (P <0.001), 7% longer clot lysis time (P = 0.004), and 31% higher maximum D-dimer levels (P <0.001) (tAble 2). Other fibrin clot variables did not differ between patients and controls. After adjustment for risk factors and medications, the intergroup differences in K s , t 50% , and D-D max remained significant. younger vs. older patients with peripheral artery disease The groups did not differ with regard to sex and body weight (tAble 1). All PAD patients had a history of smoking but current smokers represented about 50% of the subjects. Fibrinogen was 31% lower in premature PAD patients (P <0.001). There were no differences between premature and older PAD patients in the prevalence of MI, carotid artery stenosis, or multisite atherosclerosis or in the medications used (tAble 1). Twelve premature PAD patients (39%) underwent revascularization procedures in the lower limb arteries.
As shown in tAble 2, all fibrin clot parameters were similar in premature and older PAD patients despite a large intergroup difference in age (P <0.001).
Associations In premature PAD patients, there was a positive correlation between CRP and ∆Abs (r = 0.72, P <0.001), an inverse correlation Altered fibrin clot structure was demonstrated in patients with advanced CAD and survivors of MI. 14 A subset of patients with PAD and CAD displayed lower clot permeability, longer clot lysis, and faster polymerization compared with individuals without CAD symptoms. 20 We failed to observe such differences likely due to different patient characteristics and a small size of our subsets. One might suspect that PAD is potent enough to abolish additional prothrombotic alterations in fibrin clot phenotype induced by CAD. Likewise, in PAD patients, the coexistence of diabetes did not affect plasma fibrin clot properties although diabetes itself substantially worsens clot phenotype. 2, 14, 15 Similarly, abnormal fibrin clot characteristics were observed in patients with premature CAD. 17, 20 The characteristics of patients with premature CAD were similar to the present premature PAD group with high prevalence of former or current cigarette smokers.
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Our study confirms the role of systemic inflammation in PAD through negative changes in fibrin clot parameters. We demonstrated that in younger PAD patients, CRP correlated with clot permeability and maximum absorbance of a fibrin gel while ABI did not influence any fibrin clot parameters. In older PAD patients, ABI correlated with most fibrin clot parameters while CRP did not. Those differences are an unexpected and novel observation. It might be speculated that low clot permeability and susceptibility to lysis, mostly driven by elevated PAI-1, enhance the progression of PAD, leading to potent associations of ABI with plasma fibrin properties. At a younger age, systemic inflammation, reflected by CRP, accounts for unfavorable alterations in plasma fibrin clot between CRP and the lag phase (r = -0.26, P = 0.04) and K s (r = -0.34, P = 0.006) The multiple regression model incorporating all 103 patients with the lag phase as dependent variable showed no independent predictors. The multiple regression model with ∆Abs as dependent variable showed premature PAD and plasma fibrinogen as independent predictors (tAble 4). The multiple regression model with K s as dependent variable revealed that this fibrin variable was predicted by premature PAD and ABI (tAble 5). Multisite atherosclerosis was identified as the only independent predictor of t 50% (coefficient beta = -0.65, P = 0.03).
dIscussIon Our study demonstrates that plasma fibrin clot characteristics are unfavorably altered in premature PAD patients compared with control subjects, and that there are no differences between premature and older PAD patients in plasma fibrin clot parameters, although we had expected a more prothrombotic phenotype in PAD occurring at a relatively young age. However, the lack of differences in plasma clot permeability and lysability associated with the age of PAD patients clearly indicates that the early occurrence of large atherosclerotic burden in the lower extremities is characterized by particularly abnormal clot characteristics unseen at that age, similar to those observed in MI. It is known that fibrin clot parameters tend to aggravate with age in healthy individuals. 25 The effect of age on clot phenotype is likely abolished in premature PAD patients by high prevalence of cardiovascular risk factors that have already been proved to negatively affect fibrin clot characteristics, i.e., smoking, diabetes, and arterial hypertension. 2 Given the low incidence of PAD below 45 years, the present approach appears pragmatic. The current study has several limitations. First, the size of the study population is limited, which may have introduced type II errors, especially in calculations of correlation coefficients. Secondly, our analysis was based on a determination of each variable at a single time point and changes in clot variables with time cannot be excluded. Third, the scanning electron microscopy of fibrin clots has not been performed. However, functional plasma-based assays without clot dehydration may provide more relevant information on fibrin clot alterations. Our experimental approach did not allow to analyze the effect of blood cells and platelets on fibrin clot structure and function. Additional fibrin clot modifiers that have not been investigated in the current study include oxidative stress and proteins released from stimulated platelets. 28 Moreover, a potential impact of statins and antihypertensive agents on fibrin clot properties 2,14,15 has not been determined, especially that therapeutic effects of those interventions in clinical practice could be suboptimal. 29 Finally, significant associations do not necessarily mean the cause-effect relationship.
In conclusion, our findings demonstrate that plasma fibrin clots in premature PAD patients are less permeable and are lysed at a reduced rate characteristics and this effect weakens with time. It should be noted that the analysis of the whole PAD group showed the effect of both ABI and CRP on clot permeability and lysability, the 2 major variables describing clot phenotype.
Our study provides additional evidence that elevated CRP is linked to atherosclerosis in all arteries, especially in middle-aged individuals, in part through unfavorable fibrin clot phenotype. 14, 16, 21 Probably, smoking elevates plasma CRP concentrations, which is associated with pathologic clot properties, promoting thrombotic events. 26 Of note, the present study provided evidence that patients with premature PAD share common unfavorable clot features with those with premature CAD. 17, 20 This indicates that abnormal fibrin clot phenotype may characterize all patients with premature atherosclerotic vascular disease, highlighting a major, though as yet poorly described, role of abnormal fibrin formation and degradation in this clinical setting.
There were marked intergroup differences in plasma PAI-1 and tPA levels with mean PAI-1 levels 8-fold higher in premature PAD patients compared with controls. High plasma PAI-1 levels were reported in middle-aged and elderly patients with PAD 9,21 and in those with premature CAD.
Increased PAI-1 contributes to hypofibrinolysis that might result in impaired removal of thrombi from the vessels and stimulate growth of atherosclerotic plaques. Our findings, particularly high PAI-1, characterize subjects with PAD diagnosed below 55 years of age. This finding merits further investigation. The cutoff point for premature PAD in the current study was set at 55 years of age or younger, which requires some comments. De Bruijne 13 defined age for premature PAD at 45 years or compared with those made from plasma of control subjects. Of note, there are no significant differences between premature and older PAD patients in plasma fibrin clot parameters indicating potent effects of large atherosclerotic burden on fibrin clot phenotype regardless of age. This study adds new information on the links between atherosclerosis, inflammation, and coagulation, suggesting a major role of fibrin formation and degradation characteristics in the progression and vascular complications of vascular atherosclerotic disease involving the lower limbs in younger and older patients.
